Editorially Independent content supported with advertising by Genentech
Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD
Show Description +
How does treatment burden on patients and caregivers weigh on a provider’s decision to use a durable anti-VEGF agent? Priya Sharma Vakharia, MD, reviews the case of a 73-year-old patient whose family provides transportation to clinic and who has expressed that he feels like a burden to his family. Dr. Vakharia begins therapy with aflibercept (Eylea, Regeneron) before moving to faricimab (Vabysmo, Genentech). After the case is presented, Jordan M. Graff, MD, weighs in on how phase 3 clinical trial data from the TENAYA/LUCERNE studies informs his decision to use faricimab in patients such as this, and Joseph M. Coney, MD, discusses the interconnected nature between dual inhibition, retinal drying, and extended duration.
Posted: 10/03/2023
Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD
How does treatment burden on patients and caregivers weigh on a provider’s decision to use a durable anti-VEGF agent? Priya Sharma Vakharia, MD, reviews the case of a 73-year-old patient whose family provides transportation to clinic and who has expressed that he feels like a burden to his family. Dr. Vakharia begins therapy with aflibercept (Eylea, Regeneron) before moving to faricimab (Vabysmo, Genentech). After the case is presented, Jordan M. Graff, MD, weighs in on how phase 3 clinical trial data from the TENAYA/LUCERNE studies informs his decision to use faricimab in patients such as this, and Joseph M. Coney, MD, discusses the interconnected nature between dual inhibition, retinal drying, and extended duration.
Posted: 10/03/2023
Please log in to leave a comment.